PDF(Pubmed)
Abstract：
Coronavirus disease 2019 (COVID-19) caused a global calamity that forced emergency use authorization to Pfizer-BioNTech COVID-19 (BNT162b2) vaccine. It is efficacious in preventing symptomatic severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in seronegative recipients. The safety profile is still unclear; however, commonly reported symptoms post-vaccination are fatigue, headache, muscle pain, chills, and injection-site pain. COVID-19 disease elicits, to some extent, cutaneous side effects like urticaria, morbilliform rash, and chilblain-like eruption. Vaccination against COVID-19 was reported to induce similar dermatologic manifestations, such as urticarial rash, delayed large-local reaction, local injection-site reaction, and morbilliform eruption. Erythema multiforme (EM) is a rare manifestation post-vaccination, and only a few reports implicate it as a culprit in cutaneous eruptions following the BNT162b2 vaccine. This report delineates the presentation of a healthy 14-year-old girl to a dermatology clinic who developed EM post-vaccination with the first dose of BNT162b2. New-onset EM-eruption post-vaccination with BNT162b2 had been reported previously in 14 cases, and one case reported on the flare of preexisting-EM.
摘要：
2019年冠状病毒病（COVID-19）引发了一场全球灾难，迫使辉瑞-BioNTechCOVID-19（BNT162b2）疫苗获得紧急使用授权。它可有效预防血清阴性受体的有症状的严重急性呼吸综合征冠状病毒-2（SARS-CoV-2）感染。安全状况尚不清楚；然而，疫苗接种后常见的症状是疲劳，头痛,肌肉疼痛，发冷,注射部位疼痛。COVID-19疾病引发，在某种程度上,皮肤副作用如荨麻疹，麻疹病毒状皮疹,和冻疮般的喷发。据报道，针对COVID-19的疫苗接种会引起类似的皮肤病学表现，如荨麻疹，延迟的大局部反应，局部注射部位反应，和泥状喷发。多形性红斑（EM）是疫苗接种后的一种罕见表现，只有少数报道暗示它是BNT162b2疫苗后皮肤爆发的罪魁祸首。本报告描述了一个健康的14岁女孩到皮肤科诊所的情况，该女孩在接种第一剂BNT162b2疫苗后开发了EM。先前报道了14例BNT162b2疫苗接种后新发的EM爆发，1例报告了先前存在的EM耀斑。
